欢迎访问《解剖学报》官方网站！今天是
English
mTOR复合物在糖尿病肾病小鼠肾组织中的不同分布和表达
Different distribution and expression of mammalian target of rapamycin complex in the kidney of diabetic nephropathy mice
目的 探讨哺乳动物雷帕霉素靶分子复合物（mTORC）在糖尿病肾病（DN）小鼠肾组织中的分布、表达。方法 14只C57BL/6小鼠随机分成对照组和DN组，每组各7只。DN组小鼠予以链脲菌素腹腔注射建立小鼠DN模型，采用生化技术检测小鼠血、尿肌酐以及白蛋白水平，组织学染色检测肾脏病理变化，免疫荧光以及免疫印迹技术检测肾组织中mTOR、mTOR第2448位丝氨酸磷酸化修饰后mTOR(p-mTOR）、mTORC1(Raptor）、mTORC2(Rictor）以及mTOR信号通路下游的效应蛋白磷酸化S6K1(p-S6K1）的分布和表达。 结果 DN组小鼠血糖、尿白蛋白/肌酐比值明显增加(P<0.01)，肾小球明显增大(P<0.05)。mTOR、Raptor以及Rictor在正常以及DN小鼠肾皮质和髓质中均有表达，主要表达在肾小球系膜区、毛细血管袢、皮质近曲小管以及外髓和内髓集合管上皮细胞中。其中正常小鼠内髓肾组织中未见p-S6K1表达，正常以及DN小鼠肾小球中未见p-mTOR表达。免疫印迹检测表明，DN小鼠肾组织中mTOR、p-mTOR、Raptor、Rictor以及p-S6K1均明显上升(P<0.05)。 结论 mTORC广泛分布于小鼠肾组织且参与DN的发生发展，但mTOR第2448位丝氨酸磷酸化并不直接参与高血糖介导的肾小球损伤。
Objective To investigate the different distribution and expression of mammalian target of rapamycin complex (mTORC) in the kidney of diabetic nephropathy (DN) mice. Methods Fourteen eight-week-old male C57BL/6 mice were assigned to 2 groups: the control group (n=7) and the streptozotocin (STZ)-induced DN group (n=7). Blood and urinary variables including glucose, albumin, creatinine and albumin/creatinine ratio were assessed 2 weeks after STZ injection. Hematoxylin-eosin staining was performed for renal pathological analyses. The distributions of mTOR, phosph-ser2448-mTOR(p-mTOR), mTORC1(Raptor), mTORC2(Rictor) and phosph-ser240/244-S6K1 (p-S6K1) were determined by immunofluorescence. The expression levels of mTOR, p-mTOR, mTORC1(Raptor), mTORC2(Rictor), S6K1 and p-S6K1 were detected by Western blotting. Results Two weeks after STZ injection, the diabetic mice developed albuminuria (P<0.01) and renal hypertrophy (P<0.05). The immunofluorescence positive staining for mTOR, Raptor, and Rictor was distributed in the epithelial cells of proximal tubules, glomerular mesangium and capillary loops as well as the medullary collecting ducts of the control mouse kidney. These positive signals increased in the DN mouse kidney (P<0.05). However, pS6K1 was not detected in the inner medulla of control mouse and p-mTOR was not found in the glomeruli of both control and DN mice. Conclusion mTORC is widely expessed in the mouse kidney and participates in the development of DN, whereas the 2448 serine phosphorylation of mTOR may be not implicated in the hyperglycemia mediated glomerular injury.
哺乳动物雷帕霉素靶分子 / 糖尿病肾病 / Rictor / Raptor / 免疫荧光 / 免疫印迹法 / 小鼠
Mammaliam target of rapamycin / Diabetic nephropathy / Rictor / Raptor / Immunofluorescence / Western blotting / Mouse
［1］Lloberas N, Cruzado JM, Franquesa M, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats ［J］. J Am Soc Nephrol, 2006, 17(5):1395-1404.
［2］Flaquer M, Lloberas N, Franquesa M, et al. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats ［J］. Life Sci, 2010, 87(5-6):147-153.
［3］Mori H, Inoki K, Masutani K, et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential ［J］. Biochem Biophys Res Commun, 2009, 384(4):471-475.
［4］Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes ［J］. Biochem Soc Trans, 2009, 37(Pt 1):217-222.
［5］Laplante M, Sabatini DM. mTOR signaling at a glance ［J］. J Cell Sci, 2009, 122(20):3589-3594.
［6］Yao LJ, Wang JQ, Zhao H, et al. Effect of telmisartan on expression of protein kinase C-alpha in kidneys of diabetic mice ［J］. Acta Pharmacol Sin, 2007, 28(6):829-838.
［7］Yao LJ, Wang JQ, Deng AG, et al.Protein kinase C-betaI, betaII in mouse diabetic nephropathy kidney and its relation to nephroprotective actions of the angiotensin receptor blocker telmisartan［J］.National Medical Journal of China, 2007,87(28):1991-1995.(in Chinese)
姚丽君,王剑清,邓安国,等.蛋白激酶C –βI,βⅡ在糖尿病肾病小鼠肾组织中的分布、表达及替米沙坦对其影响［J］.中华医学杂志,2007,87(28):1991-1995.
［8］Duan LJ, Wang GP, Yang XG, et al. mTOR signaling pathway regulates growth of eight liver cell types during rat liver regeneration ［J］. Acta Anatomica Sinica, 2012, 43(2): 205-213. (in Chinese)
段丽娟,王改平,杨献光,等.哺乳动物雷帕霉素靶蛋白信号通路相关基因对大鼠再生肝8种细胞生长过程的调节作用［J］. 解剖学报,2012,43(2): 205-213.
［9］Lieberthal W, Levine JS. Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications ［J］. Am J Physiol Renal Physiol, 2012, 303(2):F180-F191.
［10］Laplante M, Sabatini DM. mTOR signaling in growth control and disease ［J］. Cell, 2012, 149(2): 274-293.
［11］Sakaguchi M，Isono M，Isshiki K，et al．Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice ［J］．Bioehem Biophys Res Cornmnn, 2006, 340(1): 296-301．
［12］Lieberthal W, Levine JS. Mammalian target of rapamycin and the kidney. I. The signaling pathway ［J］. Am J Physiol Renal Physiol, 2012, 303(1):F1-F10.
［13］G?del M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice ［J］. J Clin Invest, 2011, 121(6):2197-2209.
［14］Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions ［J］. Carcinogenesis, 2004, 25(11):2053-2059. ［15］Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers ［J］. Clin Cancer Res, 2004, 10(20):6779-6788.
［16］Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo ［J］. Cancer Res, 2003, 63(11):2742-2746.
［17］Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth ［J］. Oncogene, 2004, 23(34):5853-5857.
［18］Bilgen Ekim, Brian Magnuson, Hugo A, et al. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression ［J］. Mol Cell Biol, 2011, 31(14): 2787-2801.
［19］Chen Z, Dong H, Jia C, et al. Activation of mTORC1 in collecting ducts causes hyperkalemia ［J］. J Am Soc Nephrol, 2013, 24(11): Epub ahead of print.
［20］Mori H, Inoki K, Masutani K, et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential ［J］. Biochem Biophys Res Commun, 2009, 384(4):471-475.
蛋白激酶C-α在小鼠尿浓缩功能中的作用研究;SGK3缺失致Ezrin泛素化在慢性肾病中的作用及机理研究
/
| 〈 |
|
〉 |
